The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 12, 2022

Filed:

Nov. 01, 2018
Applicant:

University of Kansas, Lawrence, KS (US);

Inventors:

Thomas Yankee, Overland Park, KS (US);

John Szarejko, Liberty, MO (US);

Assignee:

University of Kansas, Lawrence, KS (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/30 (2006.01); A61K 39/39 (2006.01); C07K 14/705 (2006.01); C07K 16/28 (2006.01); C07K 14/725 (2006.01); C07K 16/00 (2006.01); A61K 38/17 (2006.01); C07K 14/495 (2006.01); C07K 14/65 (2006.01); C12N 15/113 (2010.01); C12N 15/62 (2006.01); A61K 38/10 (2006.01);
U.S. Cl.
CPC ...
C07K 16/3092 (2013.01); A61K 38/179 (2013.01); A61K 39/39 (2013.01); C07K 14/495 (2013.01); C07K 14/65 (2013.01); C07K 14/7051 (2013.01); C07K 14/70532 (2013.01); C07K 14/70578 (2013.01); C07K 14/70596 (2013.01); C07K 16/00 (2013.01); C07K 16/2803 (2013.01); C07K 16/2896 (2013.01); C07K 16/3084 (2013.01); C12N 15/113 (2013.01); C12N 15/62 (2013.01); A61K 38/10 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01); C07K 2319/42 (2013.01);
Abstract

The present disclosure generally relates to chimeric antigen receptors, more specifically to chimeric antigen receptor compositions and methods for use of the same. The present disclosure also provides for nucleic acid molecules and expression vectors for making and using the chimeric antigen receptors and for co-receptor signaling using such chimeric antigen receptors. The present disclosure also provides methods of treatment using such compositions. The chimeric antigen receptors of the present disclosure interact with the endogenous T-cell receptor complex enabling physiological control of signaling and T-cell response and can be combined with ligands such as co-stimulatory ligands for further controlling and influencing T-cell activation and response.


Find Patent Forward Citations

Loading…